Abstract: The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.
Type:
Application
Filed:
January 28, 2011
Publication date:
November 29, 2012
Applicants:
KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, HANMI PHARM. CO. LTD.
Inventors:
Seung Hyun Jung, Young Hee Jung, Wha Il Choi, Jung Beom Son, Eun Ju Jeon, In Ho Yang, Tae Hun Song, Mi Kyoung Lee, Myoung Sil Ko, Young Gil Ahn, Maeng Sup Kim, Young Jin Ham, Tae Bo Sim, Hwan Geun Choi, Jung Mi Han, Dong-sik Park, Hwan Kim
Abstract: A method and packaging machine for preparing rapidly disintegrating formulations for oral administration are disclosed. The present invention is characterized in that a powdery mixture including a pharmaceutically active ingredient and a sugar or a sugar alcohol powder is filled into a packaging material and, thereafter, the mixture, filled in the packaging material, is heated. The present invention can simply and economically prepare an oral formulation which undergoes rapid disintegration in the oral cavity and provides for high-quality administration to patients.
Type:
Application
Filed:
January 5, 2012
Publication date:
May 10, 2012
Applicant:
Hanmi Pharm. Co., Ltd.
Inventors:
Chang Hyun LEE, Jong Soo Woo, Hong Gi Yi, Kyeong Soo Kim, Ho Taek Yim
Abstract: A method and packaging machine for preparing rapidly disintegrating formulations for oral administration are disclosed. The present invention is characterized in that a powdery mixture including a pharmaceutically active ingredient and a sugar or a sugar alcohol powder is filled into a packaging material and, thereafter, the mixture, filled in the packaging material, is heated. The present invention can simply and economically prepare an oral formulation which undergoes rapid disintegration in the oral cavity and provides for high-quality administration to patients.
Type:
Grant
Filed:
December 23, 2009
Date of Patent:
March 6, 2012
Assignee:
Hanmi Pharm. Co., Ltd.
Inventors:
Chang Hyun Lee, Jong Soo Woo, Hong Gi Yi, Kyeong Soo Kim, Ho Taek Yim
Abstract: The present invention relates to a method for preparing Montelukast acid or its sodium salt by reacting a thiol compound with a Montelukast intermediate in the presence of a base in a medium comprising an ionic liquid compound. In accordance with the inventive method, highly pure Montelukast acid or its sodium salt, which is advantageously used as a raw material in the preparation of Montelukast, a leukotriene antagonist, can be easily prepared in a high yield.
Type:
Application
Filed:
October 1, 2008
Publication date:
May 5, 2011
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Chul-Hyun Park, Eun-Ju Park, Choong-Hahn Kim, Suk Man Jang, Eun Jung Lim, Young Kil Chang, Gwan Sun Lee, Jaeheon Lee
Abstract: 1-?-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivative of formula (I) having the 3-hydroxy group protected with a biphenylcarbonyl group is a solid which can be easily purified by a simple procedure such as recrystallization, and therefore, it can be advantageously used as an intermediate in the preparation of gemcitabine in a large scale. Further, the 1-?-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivative of formula (I) can be prepared with high stereoselectivity using the compound of formula (V) as an intermediate.
Type:
Grant
Filed:
June 21, 2005
Date of Patent:
December 28, 2010
Assignee:
Hanmi Pharm. Co., Ltd
Inventors:
Jaeheon Lee, Gha-Seung Park, Moonsub Lee, Han Kyong Kim, Hyo-Jeong Bang, Young-Kil Chang, Gwan Sun Lee
Abstract: The present invention relates to a novel method of preparing a taxane derivative having an anti-tumor and anti-leukemia activity, and intermediates used therein.
Type:
Application
Filed:
November 20, 2007
Publication date:
December 16, 2010
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Nam Du Kim, Wooseob Shin, Jaehyuk Jung, Dong Jun Kim, Gi Jeong Kim, Young Ho Moon, Young-Kil Chang, Gwan Sun Lee, Tae Jin Choi
Abstract: Provided is a method of preparing a (6R)-3-hexyl-4-hydroxy-6-undecyl-5,6-dihydropyran-2-one, and a (5R)-2-hexyl-5-hydroxy-3-iminohexadecanoate derivative used in said method as an intermediate.
Type:
Application
Filed:
October 29, 2008
Publication date:
October 28, 2010
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Sang Min Yun, Young Ho Moon, Young-Kil Chang, Dong Jin Hong, Ji-Yeon Chang, Moon Sub Lee, Jaeho Yoo, Ji Sook Kim, Cheol Kyung Kim
Abstract: Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs.
Type:
Application
Filed:
April 9, 2010
Publication date:
October 7, 2010
Applicant:
Hanmi Pharm, Co., Ltd.
Inventors:
Young Min KIM, Dae Jin Kim, Sung Min Bae, Chang Ki Lim, Se Chang Kwon, Gwan Sun Lee
Abstract: The present invention relates to a method for preparing capecitabine and a method for preparing a ?-anomer-rich trialkyl carbonate compound used therein, and a highly pure capecitabine can be efficiently prepared with a high yield by the method of the present invention using the ?-anomer-rich trialkyl carbonate compound as an intermediate.
Type:
Application
Filed:
November 7, 2008
Publication date:
September 30, 2010
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Jaeheon Lee, Gha-Seung Park, Weon Ki Yang, Jin Hee Kim, Cheol Hyun Park, Yong-Hoon An, Yoon Ju Lee, Young-Kil Chang, Gwan Sun Lee
Abstract: Provided is an improved method for stereoselectively preparing 2?-deoxy-2?,2?-difluorocytidine of formula (I), which includes reacting a 1-halo ribofuranose compound with a nucleobase of formula (IV) in a solvent to obtain a nucleo side of formula (II) with removal of a silyl halide ((alkyl)3SiX (X=halide)); and deprotecting the nucleoside of formula (II) to obtain 2?-deoxy-2?,2?-difluorocytidine of formula (I). 2?-Deoxy-2?,2?-difluorocytidine of formula (I) is effective for treating various cancers such as non-small cell lung (NSCLC), pancreatic, bladder, breast or ovarian cancers.
Type:
Grant
Filed:
December 29, 2005
Date of Patent:
September 21, 2010
Assignee:
Hanmi Pharm. Co., Ltd
Inventors:
Jaeheon Lee, Gha Seung Park, Moonsub Lee, Hyo-Jeong Bang, Jae Chul Lee, Cheol Kyong Kim, Chang-Ju Choi, Han Kyong Kim, Hoe Chul Lee, Young-Kil Chang, Gwan Sun Lee
Abstract: Disclosed herein is a pharmaceutical composition comprising a part containing amlodipine or a pharmaceutically acceptable salt thereof and another separate part containing losartan or a pharmaceutically acceptable salt thereof, which exhibits improved preventive and therapeutic effects against cardiovascular disorders.
Type:
Application
Filed:
December 7, 2007
Publication date:
September 16, 2010
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Jong Soo Woo, Hong Gi Yi, Moon Hyuk Chi, Kyeong Soo Kim
Abstract: Optically pure voriconazole can be prepared in a high yield by a) subjecting 1-(2,4-difluorophenyl)-2(1H-1,2,4-triazol-1-yl)ethanone to Reformatsky-type coupling reaction with a substituted thiopyrimidine derivative to obtain a desired (2R,3S)/(2S,3R)-enantiomeric pair; b) removing the thiol derivative from the enantiomer to obtain racemic voriconazole; and c) isolating the racemic voriconazole by way of optical resolution using an optically active acid.
Type:
Application
Filed:
August 4, 2008
Publication date:
July 29, 2010
Applicant:
HANMI PHARM, CO., LTD.
Inventors:
Young Ho Moon, Moon Sub Lee, Jae Ho Yoo, Ji Sook Kim, Han Kyong Kim, Chang Ju Choi, Young Kil Chang, Gwan Sun Lee
Abstract: Optically pure clopidogrel can be prepared in a high yield by optically resolving a racemic form of the compound of formula (II) using an optically active amine to form the optically active form of the compound of formula (III) or its acid-addition salt; and methylating the compound of formula (III) or its acid-addition salt.
Type:
Grant
Filed:
August 28, 2009
Date of Patent:
July 27, 2010
Assignee:
Hanmi Pharm. Co., Ltd
Inventors:
Eun Sook Kim, Hee Cheol Kim, Bo Sung Kwon, Sangmin Yun, Mi Young Ko, Cheol Kyung Kim, Kwee Hyun Suh
Abstract: A sustained release composition for oral administration of niacin, comprising niacin; a carrier for sustained release composed of a hydrophilic polymer and a hydrophobic polymer; and a pharmaceutically acceptable additive, the hydrophilic polymer being a polyethylene oxide and a natural gum, is capable of maintaining a constant release rate of niacin.
Abstract: The present invention provides a novel amide derivative and a pharmaceutically acceptable salt thereof which selectively and effectively inhibits the growth of cancer cells induced by the overexpression of an epidermal growth factor receptor and also prevents the development of drug resistance caused by the mutation of EGFR tyrosine kinase, and a pharmaceutical composition comprising same as an active ingredient.
Type:
Application
Filed:
June 5, 2008
Publication date:
July 15, 2010
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Kwang-Ok Lee, Mi Young Cha, Mi Ra Kim, Young Hee Jung, Chang Gon Lee, Se Young Kim, Keukchan Bang, Bum Woo Park, Bo Im Choi, Yun Jung Chae, Mi Young Ko, Han Kyong Kim, Young-Gil Ahn, Maeng Sup Kim, Gwan Sun Lee
Abstract: A process for stereospecific preparation of bepotastine of formula (I) and novel intermediates used therein having formulae (II) to (IV) are provided. The inventive process comprises subjecting (RS)-4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidine to a reaction with a 4-halobutanoic acid l-menthyl ester, halo being chloro, bromo or iodo, in an organic solvent in the presence of a base to produce (RS)-bepotastine l-menthyl ester of formula (II), conducting a reaction of the compound of formula (II) with N-benzyloxycarbonyl L-aspartic acid in an organic solvent to induce selective precipitation of bepotastine l-menthyl ester.N-benzyloxycarbonyl L-aspartate of formula (III), filtering the precipitates formed in step 2) to isolate the compound of formula (III), treating the compound of formula (III) with a base to liberate bepotastine l-menthyl ester of formula (IV), and hydrolyzing the compound of formula (IV) in the presence of a base.
Type:
Application
Filed:
June 5, 2008
Publication date:
July 1, 2010
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Tae Hee Ha, Chang Hee Park, Won Jeoung Kim, Soohwa Cho, Han Kyong Kim, Kwee Hyun Suh
Abstract: Disclosed is a novel use of an immunoglobulin Fc fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier. The pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the immunoglobulin Fc fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs.
Type:
Grant
Filed:
November 13, 2004
Date of Patent:
June 15, 2010
Assignee:
Hanmi Pharm. Co., Ltd
Inventors:
Young Min Kim, Dac Hae Song, Sung Youb Jung, Chang Hwan Kim, In Young Choi, Se Chang Kwon, Gwan Sun Lee
Abstract: Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs.
Type:
Grant
Filed:
November 13, 2004
Date of Patent:
June 15, 2010
Assignee:
Hanmi Pharm. Co., Ltd
Inventors:
Young Min Kim, Dae Jin Kim, Sung Min Bae, Chang Ki Lim, Se Chang Kwon, Gwan Sun Lee
Abstract: The present invention discloses a non-hygroscopic crystalline bepotastine metal salt hydrate, a method for preparing same, and a pharmaceutical composition comprising same for treating or preventing a histamine-mediated disease or an allergic disease.
Type:
Application
Filed:
April 4, 2008
Publication date:
June 3, 2010
Applicant:
Hanmi Pharm. Co., Ltd.
Inventors:
Tae Hee Ha, Chang Hee Park, Won Jeoung Kim, Hee Sook Oh, Seung Hwan Cho, Cheol Kyung Kim, Kwee Hyun Suh, Gwan Sun Lee
Abstract: A recombinant expression vector capable of expressing and secreting an antibody fragment fused with E. coli thermostable enterotoxin signal sequence derivative or E. coli outer membrane protein A (Omp A) signal sequence in the form of a soluble heterozygote protein is used to mass-produce the antibody fragment by culturing a microorganism transformed with the expression vector in a medium and collecting the antibody fragment secreted from the transformed microorganism into the medium.
Type:
Grant
Filed:
October 14, 2004
Date of Patent:
May 18, 2010
Assignee:
Hanmi Pharm. Co., Ltd
Inventors:
Sung Youb Jung, Jin Sun Kim, Se Chang Kwon, Gwan Sun Lee